Susquehanna International Group
KYMR icon

Susquehanna International Group’s Kymera Therapeutics KYMR Stock Holding History

Susquehanna International Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.37M Buy
64,500
+17,800
+38% +$1.41M ﹤0.01% 4104
2025
Q4 		$3.63M Sell
46,700
-43,900
-48% -$2.96M ﹤0.01% 4552
2025
Q3 		$5.13M Buy
90,600
+35,400
+64% +$1.6M ﹤0.01% 4053
2025
Q2 		$2.41M Buy
55,200
+22,900
+71% +$789K ﹤0.01% 5388
2025
Q1 		$884K Buy
32,300
+17,900
+124% +$653K ﹤0.01% 7556
2024
Q4 		$579K Sell
14,400
-6,100
-30% -$276K ﹤0.01% 8305
2024
Q3 		$970K Buy
+20,500
New +$905K ﹤0.01% 6851
2024
Q2 		– Sell
-6,900
Closed -$277K – 12707
2024
Q1 		$277K Sell
6,900
-12,700
-65% -$454K ﹤0.01% 9876
2023
Q4 		$499K Buy
19,600
+4,400
+29% +$78.7K ﹤0.01% 8671
2023
Q3 		$211K Buy
15,200
+200
+1% +$4.02K ﹤0.01% 10115
2023
Q2 		$345K Sell
15,000
-204,700
-93% -$5.87M ﹤0.01% 9161
2023
Q1 		$6.51M Sell
219,700
-54,800
-20% -$1.77M ﹤0.01% 3059
2022
Q4 		$6.85M Buy
274,500
+264,600
+2,673% +$7.06M ﹤0.01% 2772
2022
Q3 		$216K Buy
+9,900
New +$261K ﹤0.01% 10643
2022
Q2 		– Sell
-8,100
Closed -$343K – 13468
2022
Q1 		$343K Buy
8,100
+3,100
+62% +$131K ﹤0.01% 9936
2021
Q4 		$317K Buy
+5,000
New +$291K ﹤0.01% 10349
2021
Q3 		– Sell
-26,900
Closed -$1.3M – 13186
2021
Q2 		$1.3M Buy
+26,900
New +$1.17M ﹤0.01% 7022

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Susquehanna International Group's KYMR Position: Q1 2026 in Review

Susquehanna International Group increased its Kymera Therapeutics (KYMR) stake by 331% in Q1 2026, buying an estimated $1.54M and bringing the position to 25,403 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #6053.

Susquehanna International Group first reported a position in KYMR in Q1 2021 and has held it in 20 quarters since. The position peaked at $2.51M in Q2 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Susquehanna International Group held 25,403 shares of Kymera Therapeutics worth $2.12M as of Q1 2026.
  • Susquehanna International Group bought 19,503 Kymera Therapeutics shares in Q1 2026, an estimated $1.54M.
  • Kymera Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6053 holding.
  • Susquehanna International Group first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's Kymera Therapeutics position peaked at $2.51M in Q2 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.